Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per… was recalled on March 16, 2026 in cooperation with the U.S. Food and Drug Administration because CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit.
Cinacalcet Hydrochloride Tablets, 30 mg, 30 Tablets per bottle, Rx Only, Manufactured by: Cipla Ltd., MIDC, Patalganga, India; Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-410-02
Lot, expiry: Lot 4PB0526, 4PB0527, 4PB0528, exp September-2026; Lot 5PB0173, exp January-2027
Units affected: 113,336 bottles
Where it was sold: Nationwide in the USA
Compare the codes above against the label on your product — usually on the bottom, the back panel, or the packaging. If your unit isn't listed, it is not part of this recall.
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
Class II means the product might cause a temporary or medically reversible health problem; the chance of serious harm is remote.
Stop using the product. Return it to the place of purchase for a refund, or dispose of it. Contact the recalling firm with questions.
Contact: Recalling firm: Cipla USA, Inc.
Not sure what you're entitled to? Read our guide: what to do if your product is recalled.
Always confirm details on the official notice from the U.S. Food and Drug Administration before acting.
View official notice →The snubber circuit can emit flames if it shorts, posing a risk of serious injury due to fire hazard.
The lithium-ion battery in the recalled power banks can overheat and ignite, posing fire and burn hazards to consumers.
CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity.
Failed Dissolution Specifications
Be the first to know when products like this are recalled. Free weekly digest, unsubscribe anytime.